https://www.dsru.org/press/pharmafocus-key-trends-for-uk-drug-safety-in-2022/ 2022-04-11T13:17:42+00:00 https://www.dsru.org/press/news-medical-heart-inflammation-more-common-among-men-following-mrna-based-covid-19-vaccination/ 2022-09-28T14:05:50+00:00 https://www.dsru.org/press/pharma-jobs-dsru-says-more-research-needed-to-understand-immunocompromised-patients-responses-to-covid-19-vaccines/ 2022-09-28T14:07:20+00:00 https://www.dsru.org/press/pharmatimes-dsru-says-more-research-needed-to-understand-immunocompromised-patients-responses-to-covid-19-vaccines/ 2022-09-28T14:07:41+00:00 https://www.dsru.org/press/pink-sheet-vaccine-study-kicks-off-in-the-uk-2-7-21-covid-notebook-subscription-required/ 2022-09-28T14:08:02+00:00 https://www.dsru.org/press/pharmatimes-safety-first/ 2022-09-28T14:08:42+00:00 https://www.dsru.org/press/pharmacy-business-pharmacists-urged-to-promote-oxford-vaccine-safety-study-among-patients/ 2022-09-28T14:09:25+00:00 https://www.dsru.org/press/scrip-regulators-reassure-on-az-vaccine-safety-after-rare-side-effects-deemed-plausible/ 2022-09-28T14:10:04+00:00 https://www.dsru.org/press/financial-review-european-uk-experts-turn-up-pressure-on-astrazeneca-over-blood-clots/ 2022-09-28T14:10:31+00:00 https://www.dsru.org/press/nature-covid-vaccines-and-blood-clots-five-key-questions/ 2022-09-28T14:10:52+00:00 https://www.dsru.org/press/european-pharmaceutical-review-us-pauses-administration-of-janssen-covid-19-vaccine/ 2022-09-28T14:11:20+00:00 https://www.dsru.org/press/pharmacy-business-pharmacists-urged-to-promote-oxford-vaccine-safety-study-among-patients-2/ 2022-09-28T14:11:41+00:00 https://www.dsru.org/press/european-pharmaceutical-review-global-pharmacovigilance-observatory-to-aid-pharmas-understanding-of-regulatory-decisions-2/ 2022-09-28T14:11:58+00:00 https://www.dsru.org/press/pharmatimes-benefits-of-az-vaccine-outweigh-risks-say-mhra/ 2022-09-28T14:12:20+00:00 https://www.dsru.org/press/guardian-astrazeneca-jab-worry-may-play-into-the-hands-of-anti-vaxxers-say-tories-also-covered-by-yahoo-and-msn/ 2022-09-28T14:12:42+00:00 https://www.dsru.org/press/guardian-wednesday-briefing-keep-getting-jab-johnson-urges/ 2022-09-28T14:13:24+00:00 https://www.dsru.org/press/msn-oxford-astrazeneca-jab-could-have-causal-link-to-rare-blood-clots-say-uk-experts/ 2022-09-28T14:13:45+00:00 https://www.dsru.org/press/guardian-oxford-astrazeneca-jab-could-have-causal-link-to-rare-blood-clots-say-uk-experts/ 2022-09-28T14:14:01+00:00 https://www.dsru.org/press/ft-blood-clots-and-the-astrazeneca-covid-vaccine/ 2022-09-28T14:14:17+00:00 https://www.dsru.org/press/guardian-keep-taking-astrazeneca-jab-says-pm-as-trial-paused-to-investigate-clot-reports-7-4-21-p6-7/ 2022-09-28T14:14:40+00:00 https://www.dsru.org/press/the-bmj-covid-19-schedule-breast-screening-before-vaccine-or-4-to-6-weeks-after-to-avoid-false-positives-says-guidance/ 2022-09-28T14:14:59+00:00 https://www.dsru.org/press/daily-mail-why-are-drugs-for-the-old-tested-on-the-young/ 2022-09-28T14:15:16+00:00 https://www.dsru.org/press/https-www-dailymail-co-uk-health-article-9339743-why-drugs-old-tested-young-html/ 2022-09-28T14:15:35+00:00 https://www.dsru.org/press/european-pharmaceutical-manufacturer-oxford-astrazeneca-covid-19-vaccine-should-continue-to-be-used-uk-researchers-say/ 2022-09-28T14:15:53+00:00 https://www.dsru.org/press/pharmacy-business-pharmacists-urged-to-participate-in-oxford-vaccine-safety-study/ 2022-09-28T14:16:12+00:00 https://www.dsru.org/press/guardian-politics-live-blog-updating-on-a-range-of-covid-19-developments/ 2022-09-28T14:16:34+00:00 https://www.dsru.org/press/nursing-times-call-for-nurses-to-join-covid-19-vaccine-side-effects-study/ 2022-09-28T14:17:34+00:00 https://www.dsru.org/press/european-pharmaceutical-manufacturer-post-market-study-of-oxford-covid-19-vaccine-begins/ 2022-09-28T14:17:50+00:00 https://www.dsru.org/press/portsmouth-news-portsmouth-associate-drug-safety-unit-to-study-side-effects-of-covid-19-vaccine/ 2022-09-28T14:18:07+00:00 https://www.dsru.org/press/south-wales-argus-oxford-astrazeneca-vaccine-safety-study-wales-recruits-needed/ 2022-09-28T14:18:22+00:00 https://www.dsru.org/press/southampton-echo-southampton-drug-safety-unit-to-start-study-of-covid-19-vaccine/ 2022-09-28T14:18:40+00:00 https://www.dsru.org/press/reuters-uk-what-you-need-to-know-about-coronavirus-right-now/ 2022-09-28T14:18:58+00:00 https://www.dsru.org/press/county-press-isle-of-wight-new-vaccine-will-be-monitored-long-term-to-build-body-of-knowledge/ 2022-09-28T14:19:13+00:00 https://www.dsru.org/press/the-national-scotland-new-vaccine-will-be-monitored-long-term-to-build-body-of-knowledge/ 2022-09-28T14:19:32+00:00 https://www.dsru.org/press/thisislocallondon-new-vaccine-will-be-monitored-long-term-to-build-body-of-knowledge/ 2022-09-28T14:19:50+00:00 https://www.dsru.org/press/newsbreak-com-new-vaccine-will-be-monitored-long-term-to-build-body-of-knowledge/ 2022-09-28T14:20:08+00:00 https://www.dsru.org/press/aol-new-vaccine-will-be-monitored-long-term-to-build-body-of-knowledge/ 2022-09-28T14:20:25+00:00 https://www.dsru.org/press/msn-new-vaccine-will-be-monitored-long-term-to-build-body-of-knowledge/ 2022-09-28T14:20:40+00:00 https://www.dsru.org/press/pharmatimes-dsru-plans-post-authorisation-study-of-covid-19-vaccines-in-the-uk/ 2022-09-28T14:21:10+00:00 https://www.dsru.org/press/pharmatimes-the-covid-vaccines-safety-net/ 2022-09-28T14:21:33+00:00 https://www.dsru.org/press/european-pharmaceutical-review-drug-safety-research-unit-says-repurposed-drugs-for-covid-19-still-require-a-lot-of-testing/ 2022-09-28T14:22:04+00:00 https://www.dsru.org/press/european-pharmaceutical-manufacturer-re-purposed-drugs-for-covid-19-need-rigorous-testing/ 2022-09-28T14:22:21+00:00 https://www.dsru.org/press/pink-sheet-30-11-20-coronavirus-notepad-repurposed-drugs-need-thorough-testing-link-for-subscribers/ 2022-09-28T14:22:40+00:00 https://www.dsru.org/press/european-pharmaceutical-manufacturer-uk-research-unit-stresses-need-for-monitoring-of-newly-licensed-covid-19-vaccines/ 2022-09-28T14:23:03+00:00 https://www.dsru.org/press/pink-sheet-16-11-20-eu-mandates-monthly-safety-summaries-for-approved-covid-19-vaccines-dsru-comments-on-the-need-for-robust-post-authorisation-safety-studies/ 2022-09-28T14:23:19+00:00 https://www.dsru.org/press/pharmafocus-opportunities-and-challenges-for-re-purposing-drugs-for-covid-19-p12-nov-edition/ 2022-09-28T14:23:34+00:00 https://www.dsru.org/press/pharmafile-remdesivir-has-favourable-benefit-risk-profile-in-covid-19-but-more-data-needed-dsru-review-argues/ 2022-09-28T14:23:52+00:00 https://www.dsru.org/press/pharmatimes-co-uk-systematic-benefit-risk-study-deems-remdesivir-a-favourable-covid-19-treatment/ 2022-09-28T14:24:06+00:00 https://www.dsru.org/press/the-scientist-scientists-voice-concerns-over-russian-covid-19-vaccine/ 2022-09-28T14:24:23+00:00 https://www.dsru.org/press/chemistry-world-russian-covid-19-vaccine-data-raises-questions/ 2022-09-28T14:24:38+00:00 https://www.dsru.org/press/pink-sheet-coronavirus-notebook-convalescent-plasma-will-it-recover-from-setbacks/ 2022-09-28T14:24:47+00:00 https://www.dsru.org/press/bmj-covid-19-us-fda-fires-spokesperson-over-misleading-claims-about-convalescent-plasma-summary-of-dsrus-benefit-risk-research-included/ 2022-09-28T14:25:01+00:00 https://www.dsru.org/press/pink-sheet-coronavirus-notebook-convalescent-plasma-will-it-recover-from-setbacks-2/ 2022-09-28T14:25:16+00:00 https://www.dsru.org/press/bmj-covid-19-us-fda-fires-spokesperson-over-misleading-claims-about-convalescent-plasma-summary-of-dsrus-benefit-risk-research-included-2/ 2022-09-28T14:25:35+00:00 https://www.dsru.org/press/pink-sheet-coronavirus-notebook-post-authorization-studies-dsrus-one-million-study-to-monitor-covid-19-vaccines-was-mentioned-in-pink-sheets-weekly-roun/ 2022-09-28T14:25:47+00:00 https://www.dsru.org/press/european-pharmaceutical-review-covid-19-vaccines-to-be-monitored-post-marketing-by-consortium-in-the-uk/ 2022-09-28T14:26:02+00:00 https://www.dsru.org/press/european-pharmaceutical-manufacturer-post-market-study-to-monitor-safety-and-effectiveness-of-covid-19-vaccines/ 2022-09-28T14:26:17+00:00 https://www.dsru.org/press/pharmafield-one-million-study-to-monitor-covid-19-vaccine-safety-and-effectiveness/ 2022-09-28T14:26:32+00:00 https://www.dsru.org/press/pink-sheet-coronavirus-notebook/ 2022-09-28T14:26:50+00:00 https://www.dsru.org/press/pharmafield-no-clear-benefit-of-hiv-antivirals-for-covid-19-patients-says-study/ 2022-09-28T14:27:10+00:00 https://www.dsru.org/press/european-pharmaceutical-review-consortium-established-to-monitor-covid-19-vaccines-after-marketing/ 2022-09-28T14:27:28+00:00 https://www.dsru.org/press/pharmatimes-new-consortium-will-monitor-safety-efficacy-of-covid-19-vaccines/ 2022-09-28T14:27:44+00:00 https://www.dsru.org/press/the-courier-dundee-and-st-andrews-universities-spearheading-covid-19-vaccine-studies/ 2022-09-28T14:28:03+00:00 https://www.dsru.org/press/pharmaceutical-technology-uk-researchers-form-consortium-to-monitor-covid-19-vaccines/ 2022-09-28T14:28:19+00:00 https://www.dsru.org/press/european-pharmaceutical-manufacturer-consortium-formed-to-assess-safety-of-covid-19-vaccines/ 2022-09-28T14:28:32+00:00 https://www.dsru.org/press/pharmafield-new-consortium-to-monitor-safety-and-effectiveness-of-covid-19-vaccines/ 2022-09-28T14:28:49+00:00 https://www.dsru.org/press/pharmafile-new-uk-consortium-established-to-monitor-covid-19-vaccine-efficacy-once-they-hit-market/ 2022-09-28T14:29:10+00:00 https://www.dsru.org/press/pink-sheet-new-consortium-to-monitor-whether-covid-19-vaccines-work-as-they-should/ 2022-09-28T14:29:29+00:00 https://www.dsru.org/press/pharmatimes-pharmatimes-talks-to-professor-saad-shakir/ 2022-09-28T14:30:04+00:00 https://www.dsru.org/press/pharmatimes-remdesivir-for-covid-19-patients-is-favourable-study-finds/ 2022-09-28T14:30:23+00:00 https://www.dsru.org/press/pharmafile-therapeutic-areas-in-focus-direct-oral-anticoagulants-examining-their-use-in-a-real-world-secondary-care-setting-vol-69-spring-2020-p32-34/ 2022-09-28T14:30:37+00:00 https://www.dsru.org/press/european-pharmaceutical-review-cytokine-storms-a-major-killer-in-patients-with-severe-covid-19-infection/ 2022-09-28T14:30:56+00:00 https://www.dsru.org/press/drug-target-review-cytokine-storms-a-major-killer-in-patients-with-severe-covid-19-infection/ 2022-09-28T14:31:14+00:00 https://www.dsru.org/press/pharmaceutical-journal-buprenorphine-implant-beneficial-for-patients-with-opioid-dependency/ 2022-09-28T14:31:29+00:00 https://www.dsru.org/press/pharmafocus-the-need-for-evolution-in-pharmacovigilance-p16-17-march-2020-edition/ 2022-09-28T14:31:48+00:00 https://www.dsru.org/press/pharmatimes-bmj-journal-deems-opioid-dependency-implant-more-favourable-than-tablets/ 2022-09-28T14:32:04+00:00 https://www.dsru.org/press/pharmatimes-improve-brand-and-batch-number-recording-urge-drug-safety-professionals/ 2022-09-28T14:32:36+00:00 https://www.dsru.org/press/pharmafield-better-recording-of-biologic-medicines-brand-and-batch-numbers-needed-for-patient-safety/ 2022-09-28T14:32:56+00:00 https://www.dsru.org/press/european-pharmaceutical-magazine-improvements-needed-in-biologics-traceability-to-ensure-patient-safety/ 2022-09-28T14:33:15+00:00 https://www.dsru.org/press/pharmaceutical-journal-researchers-unable-to-identify-batches-of-biologic-drugs-from-85-of-yellow-card-report/ 2022-09-28T14:33:32+00:00 https://www.dsru.org/press/pharmatimes-is-the-uk-facing-its-own-opioid-crisis/ 2022-09-28T14:33:59+00:00 https://www.dsru.org/press/the-bmj-gps-are-urged-to-help-monitor-new-drugs/ 2022-09-28T14:34:23+00:00 https://www.dsru.org/press/daily-mail-last-resort-pill-that-brings-nightmares-p-5-august-print-edition/ 2022-09-28T14:34:40+00:00 https://www.dsru.org/press/lbc-radio-dsru-director-saad-shakir-interviewed-for-lbc-radio-about-the-adverse-side-effects-of-anti-malaria-drug-mefloquine-in-relation-to-the-death-of-student-alana-cutland/ 2022-09-28T14:34:50+00:00 https://www.dsru.org/press/european-pharmaceutical-manufacturer-magazine-use-of-real-world-data-important-for-improving-medicine-safety/ 2022-09-28T14:35:12+00:00 https://www.dsru.org/press/onmedica-treatment-for-hyperthyroidism-linked-to-increased-risk-of-cancer-death/ 2022-09-28T14:35:30+00:00 https://www.dsru.org/press/daily-mail-taking-heartburn-pills-doubles-your-risk-of-developing-an-allergy-because-suppressing-stomach-acid-destroys-the-bodys-defense-barrier/ 2022-09-28T14:35:57+00:00 https://www.dsru.org/press/pharma-times-big-pharma-come-back-to-mental-health-and-invest-in-europe/ 2022-09-28T14:36:16+00:00 https://www.dsru.org/press/pharma-times-big-pharma-come-together-for-better-drug-side-effect-detection/ 2022-09-28T14:36:35+00:00 https://www.dsru.org/press/pink-sheet-new-international-signal-detection-initiative-to-influence-industry-practice/ 2022-09-28T14:36:55+00:00 https://www.dsru.org/press/pharmaceutical-journal-pharmaceutical-companies-vow-to-improve-monitoring-of-medicine-side-effects/ 2022-10-14T08:34:06+00:00 https://www.dsru.org/press/european-pharmaceutical-review-how-can-evidence-based-medicine-ebm-methodology-support-drug-withdrawals-2/ 2022-11-10T15:03:07+00:00 https://www.dsru.org/press/pink-sheet-evusheld-uk-urged-to-use-rwd-to-give-clinically-vulnerable-early-access-to-covid-19-treatment/ 2022-11-10T15:03:31+00:00 https://www.dsru.org/press/bmj-evusheld-government-is-urged-to-expedite-covid-antibody-treatment-for-vulnerable-patients/ 2022-11-10T15:03:57+00:00 https://www.dsru.org/press/guardian-windmills-of-your-mind-viral-covid-jab-hack-placebo-effect-at-best-say-doctors/ 2022-11-25T08:31:42+00:00 https://www.dsru.org/press/epm-magazine-flu-vaccine-monitoring-in-the-uk-to-include-teenagers-for-the-first-time/ 2022-11-25T08:32:26+00:00 https://www.dsru.org/press/epm-magazine-the-medtalk-podcast-understanding-covid-19-vaccines-with-the-dsru/ 2022-11-25T08:33:03+00:00 https://www.dsru.org/press/event-horizon-three-years-on-how-did-the-pandemic-transform-pharmacovigilance/ 2023-06-02T09:27:32+00:00 https://www.dsru.org/press/online-surveys-key-to-safety-data-for-novel-vaccines-concludes-report/ 2023-06-02T09:28:05+00:00 https://www.dsru.org/press/web-based-surveys-offer-a-feasible-way-to-monitor-the-safety-of-novel-vaccines/ 2023-06-02T09:28:25+00:00 https://www.dsru.org/press/understanding-the-evidence-used-in-drug-product-withdrawals/ 2024-02-12T12:22:18+00:00 https://www.dsru.org/press/southampton-scientist-internationally-recognized-through-award-win/ 2024-02-12T12:40:38+00:00 https://www.dsru.org/press/the-therapy-suite/ 2024-02-12T14:10:02+00:00 https://www.dsru.org/press/the-eliminator/ 2024-02-27T15:27:18+00:00 https://www.dsru.org/press/understanding-the-evidence-used-in-drug-product-withdrawals-2/ 2025-06-10T09:35:53+00:00 https://www.dsru.org/press/evidence-use-for-product-withdrawal-is-leaning-toward-observational-research/ 2025-06-10T09:36:52+00:00 https://www.dsru.org/press/study-links-covid-19-and-some-vaccines-to-increased-risk-of-rare-neurological-condition/ 2025-06-10T09:37:54+00:00 https://www.dsru.org/press/uk-study-reveals-long-term-safety-of-covid-19-vaccine/ 2025-06-10T09:38:29+00:00 https://www.dsru.org/press/dsru-appoints-linda-harmark-as-director/ 2025-06-10T09:39:00+00:00 https://www.dsru.org/press/drug-safety-research-unit-announces-new-director/ 2025-06-10T09:39:27+00:00 https://www.dsru.org/press/the-drug-safety-research-unit-has-announced-linda-harmark-as-its-new-director/ 2025-06-10T09:40:05+00:00 https://www.dsru.org/press/alzheimers-drug-requires-strengthened-pharmacovigilance-approach/ 2025-06-10T09:40:36+00:00 https://www.dsru.org/press/the-approval-of-lecanemab-a-pharmacovigilance-perspective/ 2025-06-10T09:41:12+00:00 https://www.dsru.org/press/revised-additional-risk-minimisation-guidelines-change-for-the-better/ 2025-06-10T09:42:07+00:00 https://www.dsru.org/press/real-world-safety-studies/ 2025-06-10T09:43:07+00:00 https://www.dsru.org/press/move-of-the-month-dr-alison-evans-appointed-head-of-education-and-training-at-drug-safety-research-unit/ 2025-06-10T09:43:54+00:00 https://www.dsru.org/press/changing-faces-may-june-2024-government-non-profit-and-professional-organisation/ 2025-06-10T09:44:29+00:00 https://www.dsru.org/press/the-drug-safety-research-unit-dsru-has-announced-dr-alison-evans-as-its-new-head-of-education-and-training/ 2025-06-10T09:45:36+00:00 https://www.dsru.org/press/director-of-the-drug-safety-research-unit-to-step-down-next-year/ 2025-06-10T09:46:09+00:00 https://www.dsru.org/press/resignation-of-dsru-director-triggers-search-for-successor/ 2025-06-10T09:46:54+00:00 https://www.dsru.org/press/30-years-at-the-forefront-of-pharmacovigilance-saad-shakirs-remarkable-journey/ 2025-06-10T09:47:39+00:00 https://www.dsru.org/press/health-industry-leaders-issue-04/ 2025-06-10T09:48:24+00:00